Therapeutic agents

Details Therapeutic agents Therapeutic agents

2004-12-30

2009-02-10

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acids and salts thereof

C562S430000, C562S451000, C562S507000, C562S508000, C560S012000, C560S042000, C560S125000, C560S126000, C546S245000, C546S314000, C544S386000, C564S161000, C564S162000

Reexamination Certificate

active

07488844

ABSTRACT:
The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

REFERENCES:
patent: 2928840 (1960-03-01), Shapiro et al.
patent: 3244398 (1966-04-01), Scaramamucci
patent: 4735959 (1988-04-01), Grell
patent: 5210208 (1993-05-01), Huang et al.
patent: 5216167 (1993-06-01), Grell et al.
patent: 6143769 (2000-11-01), Grell et al.
patent: 6258850 (2001-07-01), Andersson
patent: 6410585 (2002-06-01), Larsen et al.
patent: 6596751 (2003-07-01), Fujita et al.
patent: 6884821 (2005-04-01), Shinoda et al.
patent: 7256307 (2007-08-01), Alstermark Lindstedt et al.
patent: 2005/0131068 (2005-06-01), Alstermark et al.
patent: 2005/0148656 (2005-07-01), Li et al.
patent: 2005/0171204 (2005-08-01), Lindstedt et al.
patent: 2006/0111406 (2006-05-01), Crespo et al.
patent: 2006/0142389 (2006-06-01), Aurell et al.
patent: 2006/0142392 (2006-06-01), Aurell et al.
patent: 2006/0194879 (2006-08-01), Ragnar et al.
patent: 2006/0258866 (2006-11-01), Li et al.
patent: 660266 (1965-08-01), None
patent: 266121 (1913-10-01), None
patent: 807687 (1951-07-01), None
patent: 1935758 (1970-02-01), None
patent: 2130282 (1971-12-01), None
patent: 2160380 (1973-06-01), None
patent: 2828222 (1980-01-01), None
patent: 1167357 (2000-10-01), None
patent: 2245624 (1975-04-01), None
patent: 2001-261612 (2001-09-01), None
patent: WO 92/05145 (1992-04-01), None
patent: WO 96/40201 (1996-12-01), None
patent: WO 99/11606 (1999-03-01), None
patent: WO 99/24442 (1999-05-01), None
patent: WO 00/59889 (2000-10-01), None
patent: WO 00/61582 (2000-10-01), None
patent: WO 00/61585 (2000-10-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/75103 (2000-12-01), None
patent: WO 01/25181 (2001-12-01), None
patent: WO 02/44127 (2002-06-01), None
patent: WO 02/44130 (2002-06-01), None
patent: WO 02/064549 (2002-08-01), None
patent: WO 02/083616 (2002-10-01), None
patent: WO 03/051822 (2003-03-01), None
patent: WO 03/051821 (2003-06-01), None
patent: WO 2004/056748 (2004-07-01), None
patent: WO 2004/000789 (2004-12-01), None
patent: WO 2004/113270 (2004-12-01), None
Adamczyk, Maciej, et al., “Use of Lipase for Regioselective One Pot Amidation and Hydrolysis,” HCAPLUS 130:251916 (1999).
Azzolina, Ornella, et al. “Antiphlogistics Aryloxypropionic Acids: Configurational Study,” HCAPLUS 120:133356 (1994).
Bagley, Scott, et al., “Phenoxyphenylacetic Acids and Derivatives Useful as Endothelin Antagonists,” HCAPLUS 125:328289 (1996).
Bagley, Scott, et al., “Preparation of Phenoxyphenlacetic Acid-Derivative Endothelin Antagonists,” HCAPLUS 125:58490 (1996).
Bagley, Scott, et al., “Preparation of Phenoxyphenylacetates and Analogs as Endothelin Receptor Antagonist,” HCAPLUS 129:67607 (1998).
Barrie, S. E. et al., “A Reappraisal of the Effect Upon Thymidine Kinase of Thymidine Derivatives Carrying Large Groups at the 5′-Position,” J. Med. Chem., vol. 27, No. 8, pp. 1044-1047 (1984).
Bauer, Klaus, et al., “Phenoxyalkane- and pheroxyalkene Carboxylic Acid, Their Derivatives and Their Use,” HCAPLUS 96:7068 (1982).
Beckh, Hansjoerg, et al., “Preparation of Sulfonamides Containing Tetrazolyl Groups and Their Use as Drugs,” HCAPLUS 113:59148 (1990).
Berge, John, et al., “Tertiary Phenethylamines,” HCAPLUS 104:5623 (1986).
Bohlmann, Ferdinand, et al., “Polyacetylene Compounds CIX. Synthesis of Natrally Occurring, Aromatic substituted Acetylene compounds,” HCAPLUS 65:99100 (1966).
Chandrakumar, Nizal Samuel, et al., “LTA4-Hydrolase Inhibitors, Pharmaceutical Compositions, and Methods of Use,” HCAPLUS 125:142725 (1996).
Chandrakumar, Nizal Samuel, et al., “Preparation of Heterocyclic LTA4 Hydrolase Inhibitors,” HCAPLUS 125:142545 (1996).
De Marchi, F., et al., “Synthesis and Pharmacological Evaluation of Some N-diethylaminoethylaryloxyacetamides and related Compounds,” HCAPLUS 79:78343 (1973).
Eakin Murdoch Allan, et al., “Preparation of N-(2-phenoxyethyl)-2-hydroxy-3-thienyloxypropylamines and Analogs as Thermogenic Agents,” HCAPLUS 114:163992 (1991).
Fex, Thomas, et al., “Preparation of N-aralkoxy-N-aralkylureas and Analogs as Antitumor Agents,” HCAPLUS 124:201795 (1995).
Cantello, Barrie Christian Charles, “2-Aminoethyl Ether Derivatives, and Their Pharmaceutical Compositions,” HCAPLUS 101:6799 (1984).
Greenlee, William J., et al., “Phenoxyphenylacetic Acid Derivatives Useful as Endothelin Antagonists,” HCAPLUS 122:31129 (1995).
Hankovszky, H. O., et al., “Benzazoles. VI. O-Alkylation of 2-(hydroxyphenyl)- and 2-(hydroxybenzyl) Benzazoles,” HCAPLUS 69:106619 (1968).
Harvey, Charolette, M., et al., “Preparation of Endothelin Receptor Antagonists for the Treatment of Emesis,” HCAPLUS 125:114587 (1996).
Hayashi, Tetsuyoshi, et al., “Insect Juvenile Hormone Mimetic activity of (4-substituted)phenoxyalkyl Compounds with Various Nitrogenous and Oxygenous Functions and Its Relationship to Their Electrostatic and Stereochemical Properties,” HCAPLUS 115:250297 (1991).
Hideg, Kalman, et al., “Alkylbenzazoles,” HCAPLUS 69:36127 (1968).
Iijima, Ikuo, et al., “Preparation of [(sulfonylamino)phenoxy]alkanoic acids as Antilipemics,” HCAPLUS 118:6741 (1993).
Iijima, Ikuo, et al., “Preparation of p-(sulfonylaminoalkyl)phenoxyalkanoic Acid Derivatives as Antilipidemics,” HCAPLUS 121:82733 (1994).
Iwakuma, Takeo, et al., “Phenoxyacetic Acids as Thromboxane A2 Antagonists and Their Preparation,” HCAPLUS 112:76612 (1990).
Iwamura, Hajime, et al., “Preparation of Phenolic Ethers as Insecticides,” HCAPLUS 116:128359 (1992).
Kraska, Allen R., “Compounds Derived from Formylphenoxyacetic Acid as Antiviral Agents in Animals,” HCAPLUS 96:34915 (1982).
Large, M. S., Smith, L.H., “β-Asrenergic Blocking Agents. 23. 1-[(Substituted-amindo)phenoxy]-3-[[(substituted-amido)alkyl]amino]propan-2-ols,” J. Med. Chem., vol. 26, No. 3, pp. 352-357 (1983).
Nametkin, et al., “Synthesis of Some Alkyl- and Aralkylphenoxyactic Acids and Their Derivatives,” ZH. Obshch. Khim., 21, pp. 2146-2147 (1951).
Nametkin, S. S., et al., “Synthesis of Some Alkyl- and Aralkylphenoxyacetic Acids and Their Derivatives,” HCAPLUS 46:48488 (1952).
Penning, Thomas D. et al., “Structure-Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A4(LTA4) Hydrolase,” HCAPLUS 132:245841 (2000).
Reiffen, Manfred, et al., “Preparation of 2-thiazolyl- and 2-oxazolyl-2-alkoxy-1-aminoethane Derivatives as Antidiabetics and Antiobesity Agents,” HCAPLUS 108:221694 (1988).
Reiffen, Manfred, et al., “Preparation of Oxazole- and Thiazoleethanamines as Antidiabetics, Antiatherosclerotics, and Antiobesity Agents,” HCAPLUS 108:150463 (1988).
Sano, Hidekazu, et al., “Reversible Thermal Printing Material Containing Imide Compound as Decoloration Accelerator,” HCAPLUS 136:191709 (2002).
Sano, Hidekazu, et al., “Reversible Thermal Recording Material Containing Cyano Compound as Decoloration Accelerator,” HCAPLUS 136:175486 (2002).
Sasaki, Yasuhiko, et al., “Preparation of 4-(2-sulfonylaminoethyl)phenol Ethers as Thromboxane A2 Antagonists,” HCAPLUS 116:105828 (1992).
Stubenrauch, Gerd, et al., “Fungicidal 1,2,4-triazol-1-yl Compounds,” 94:15736 (1981).
Svab, A., et al., “Some 3-substituted Derivatives of 5-methylisoxazole with an Antiparasitic Effect,” HCAPLUS 100:82623 (1984).
Tamiz, Amir P., et al., “Structure-Activity Relationship of N-(Phenyla

Affiliated with

Also associated with

Rating

Therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4074652